SecBot SecBot

STRO drug pipeline

SUTRO BIOPHARMA, INC. · 3 rated drugs
$9.32
−5.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
3 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketStill in Phase 1 dose escalation; assuming successful Phase 1/2 and pivotal trials, potential approval would be several years away, likely 2029 or later.

STRO-004 Not publicly disclosed (no generic/INN name found in available sources) Updated Nov 13

What to watch

The Phase 1 dose-escalation data from August 2026 showed early signals of activity (confirmed and unconfirmed partial responses) but also dose-limiting toxicities at the highest dose. The next update in H1 2027 will include expansion cohorts and more mature efficacy/safety data. Investors should watch for the dose selected for expansion, the durability of responses, and whether the safety profile supports a competitive advantage over the approved tissue-factor ADC Tivdak (tisotumab vedotin).

Bull case
  • Early Phase 1 data showed confirmed and ongoing unconfirmed partial responses in heavily pretreated patients with pancreatic, head and neck, and NSCLC cancers, suggesting clinical activity. (Source: Sutro Q2 2026 earnings press release, August 12, 2026)
  • The drug uses a high DAR-8 exatecan payload with Sutro's site-specific conjugation technology, which preclinical data suggested may offer improved efficacy versus benchmark TF-targeting ADCs. (Source: AACR 2026 preclinical data presentation, April 2026)
  • Analyst consensus is strongly bullish: 18 buy/strong-buy ratings, mean price target ~$47.23 vs current ~$9.73, implying roughly 390% upside.
Bear case
  • Dose-limiting toxicities were reported at the highest dose level in the Phase 1 study, raising questions about the therapeutic window. (Source: Benzinga summary of August 2026 STRO-004 update)
  • The stock fell sharply after the August 2026 Phase 1 update, suggesting the market was not impressed by the early data. (Source: MSN/SeekingAlpha coverage, August 12, 2026)
  • Tivdak (tisotumab vedotin) from Genmab is already approved for recurrent cervical cancer, establishing a competitive benchmark that STRO-004 must beat on efficacy or safety. (Source: Medscape/ASCO publications)
● neutral
Impact
PhasePreclinical
Time to marketYears away; the drug is still in preclinical development with no IND filed as of November 2026. Even after IND clearance, Phase 1, 2, and 3 trials typically take 5-8 years before potential approval.

STRO-227 Updated Nov 13

What to watch

STRO-227 is an early-stage, preclinical asset with no human data and no confirmed IND timeline. Investors should watch for an IND filing announcement or a pipeline update from Sutro that clarifies whether STRO-227 remains on track. The stock's primary near-term catalyst is the STRO-004 Phase 1 data update expected in the first half of 2027, not STRO-227.

Bull case
  • STRO-227 showed meaningful, dose-dependent antitumor activity in preclinical solid tumor models at AACR 2026, alongside STRO-006.
  • Sutro's site-specific ADC platform has shown early clinical validation through STRO-004's Phase 1 partial responses, which may de-risk the broader pipeline including STRO-227.
  • The dual-payload design is a novel approach that could differentiate STRO-227 from other PTK7-targeting ADCs if it reaches the clinic.
Bear case
  • STRO-227 is still preclinical with no IND filed as of November 2026, despite a prior guidance for 2026 IND submission.
  • The drug has no human safety or efficacy data; preclinical results often fail to translate to clinical success.
  • Sutro underwent a major restructuring in 2025-2026 including layoffs, a reverse stock split, and the loss of a major partnership (Ipsen returned ROR1 ADC in August 2025), raising questions about pipeline prioritization and resources.
● neutral
Impact
PhasePreclinical (IND submitted/planned; Phase 1 initiation guided for Q3 2026)
Time to marketUnknown — years away. If Phase 1 begins on schedule (Q3 2026 guidance), first human safety data would likely come in 2027; any approval would be many years later, assuming the program survives early trials.

STRO-006 Updated Sep 11

What to watch

Watch for the company's confirmation that STRO-006 has entered Phase 1 (guided for Q3 2026), an operational milestone, not a data readout. The defining catalyst for Sutro's share price is STRO-004's expansion-cohort data (H1 2027 per the Q2 2026 release risk list), so treat STRO-006's near-term impact as modest pipeline news flow, not a binary.

Bull case
  • Platform validation: STRO-006 is one of three next-gen ADCs (STRO-004, STRO-006, STRO-227) that AACR 2026 preclinical data showed with 'robust antitumor activity and favorable safety profiles', positive data reinforce confidence in Sutro's conjugation platform
  • Specific positive preclinical signal: STRO-006 demonstrated dose-dependent antitumor activity in NSCLC and head-and-neck cancer models, per the AACR 2026 press release
  • Clear near-term execution milestone: company guided STRO-006 Phase 1 initiation for Q3 2026 in its August 12, 2026 release, so the program is moving toward the clinic on schedule
Bear case
  • Preclinical stage, no human data: STRO-006 has not entered a clinical trial, preclinical mouse-model activity frequently fails to translate to patients
  • Not the lead program: STRO-006 is a smaller part of a multi-program pipeline; STRO-004 (Phase 1, tissue-factor ADC) is the primary value driver, so STRO-006 news alone moves STRO shares less
  • A Phase 1 start is an operational milestone, not a data readout, no efficacy binary until first clinical data, likely well into 2027

Other drugs in filings and trials

no drug report yet

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
STRO-002A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid TumorsPhase 2Completed19Jun 6, 2025
Luveltamab tazevibulinLuveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AMLPhase 2Terminated · results1Jan 21, 2025